USA Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of generic medicines now available on the American market. In a recent interview with PharmaBoardroom, Biocon’s Commercial Head Global Generics & SVP Marketing Abhijit Zutshi outlined the company’s recipe…
Coronavirus Sophia Ononye-Onyia outlines the key failings in the USA’s response to the coronavirus outbreak and why greater numbers of inter-industry partnerships and increased technological uptake are key to fighting this crisis and reframing the US life sciences industry of the future. Imagine if we invested billions in epidemiological surveillance…
USA KV Kumar, head of the Indian American International Chamber of Commerce, gives an account of the bilateral trade relations between India and the US and candidly speaks about the opportunities for Indian generic companies in the world’s largest pharmaceutical market. He addresses the need for supply chain diversification in light…
USA Abhijit Zutshi, commercial head global generics & SVP marketing at Indian firm Biocon highlights the challenges inherent in the US generics market, the process of setting up an affiliate in the US, and how Biocon’s level of vertical integration allows it to be highly competitive and stand out from the…
USA Dan Leonard is president & CEO of the National Pharmaceutical Council, which sponsors and participates in research on the appropriate use of pharmaceuticals and the clinical and economic value of pharmaceutical innovation. Leonard outlines the activities of the Council – which celebrated its 65th anniversary in 2018 – his priorities…
Opinion John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the past risk getting left behind. “Drug” companies have a unique opportunity to invent a different market for themselves. It…
Romania Dan Minoiu, partner at Romanian law firm Mușat & Asociații, shares his insights into the main trends shaping the healthcare environment in Romania from a regulatory and legal perspective, the challenges currently facing his clients, and his hopes for the future of the country. Our clients always stress how…
Opinion AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the ongoing coronavirus pandemic. Like the rest of society, executive and scientific teams working in the US generic and biosimilar pharmaceutical industries have never experienced anything quite…
Artificial Intelligence Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria strains via a deep learning algorithm. AI has the power to enable biopharmaceutical companies to reduce costs and improve…
India The US generics market stood at USD 69 billion in 2018 and is expected to grow to USD 86 billion by 2022. Made with Visme Infographic Maker Abbreviated New Drug Applications (ANDAs), whereby a company seeks authorisation from the US FDA for a generic copy of a previously approved…
India A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in the USA, generic drugs play a vital role within US healthcare and have come a long way since their use…
Coronavirus Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself as the frontrunner in personalized healthcare. In 2012, CEO Severin Schwan set the ambitious target of pairing more than 60…
See our Cookie Privacy Policy Here